Blog | 12/8/2025

Investor-ready Evidence Planning: Why a Robust Strategy Matters to Funders

By Nichola Gokool, Vice President, Customer Strategy and Innovation, Medical Communications and Doug Mullen, PhD, Vice President and Co-Head of Biopharma Transaction Advisory and Rare Disease Practices at Health Advances

Outside funding is critical to the work of a biotech company. To attract venture capitalists or strategic partners, you’ll need a compelling investment thesis built on evidence you’ve already generated and expect to generate throughout development.

Investor-ready Evidence Planning: Why a Robust Strategy Matters to Funders

Outside funding is critical to the work of a biotech company. To attract venture capitalists or strategic partners, you’ll need a compelling investment thesis built on evidence you’ve already generated and expect to generate throughout development.

Read more.